We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.
OK
 

Key Financials

 

Key figures (IFRS) Galapagos group (unaudited)

(thousands of €, if not stated otherwise) 31/03/2018 31/03/2017
INCOME STATEMENT
Revenues (*) 37,907 33,992
Other income 6,931 5,871
R&D expenditure (69,765) (44,930)
S, G&A expenses (7,110) (6,158)
Operating expenses (76,875) (51,088)
Operating loss (32,036) (11,225)
Net financial results (5,184) (2,380)
Taxes (62) -
Net loss (37,283) (13,605)
 
BALANCE SHEET 31/03/2018 31/12/2017
Cash and cash equivalents 1,108,186 1,151,211
R&D incentives receivables 80,870 75,783
Assets 1,229,864 1,286,274
Shareholders' equity (*) 899,345 1,011,983
Deferred income (*) 268,654 219,892
Other Liabilities 61,865 54,399
 
CASH FLOW 31/03/2018 31/03/2017
Operational cash burn (**) (41,335) (23,878)
Cash flow generated / used (-) in financing activities 3,905 (14)
Effect of currency exchange rate fluctuation on cash and cash equivalents (5,595) (2,496)
Decrease in cash and cash equivalents (43,025) (19,856)
Cash and cash equivalents on 31 March 1,108,186 953,385
 
FINANCIAL RATIOS 31/03/2018 31/03/2017
Number of shares issued on 31 March 51,234,962 46,256,078
Basic and diluted loss per share (in €) (0.73) (0.29)
Share price on 31 March (in €) 81.30 81.58
Total group employees on 31 March (number) 634 530

Employees per site as of 31 March 2018

(*) Our revenues, shareholders' equity and deferred income for the period ended 31 March 2018 were influenced by the adoption of the new standard IFRS 15 - Revenue from contract with customers, on 1 January 2018. We refer to the notes of our Q1 2018 interim consolidated financial report for additional information.

(**) The operational cash burn (or operational cash flow if this performance measure is positive) is equal to the sum of the net cash flows generated / used (-) in operating activities and the net cash flows generated / used (-) in investing activities minus (i) the proceeds or cash used, if any, in acquisitions or disposals of businesses; and (ii) the movement in restricted cash, if any. This alternative performance measure is in our view an important metric for a biotech company in the development stage.